EA201170336A1 - Пептиды амброзии для получения вакцин - Google Patents

Пептиды амброзии для получения вакцин

Info

Publication number
EA201170336A1
EA201170336A1 EA201170336A EA201170336A EA201170336A1 EA 201170336 A1 EA201170336 A1 EA 201170336A1 EA 201170336 A EA201170336 A EA 201170336A EA 201170336 A EA201170336 A EA 201170336A EA 201170336 A1 EA201170336 A1 EA 201170336A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ragweed
relates
ambrosia
peptides
compositions
Prior art date
Application number
EA201170336A
Other languages
English (en)
Inventor
Марк Лярш
Родерик Питер Хэфнер
Пол Лэйдлер
Original Assignee
Серкешиа Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41090318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201170336(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0814986A external-priority patent/GB0814986D0/en
Priority claimed from PCT/GB2008/002779 external-priority patent/WO2009022155A2/en
Priority claimed from GB0815218A external-priority patent/GB0815218D0/en
Application filed by Серкешиа Лимитед filed Critical Серкешиа Лимитед
Publication of EA201170336A1 publication Critical patent/EA201170336A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Настоящее изобретение относится к композициям для профилактики или лечения аллергии на амброзию путем толеризации. Композиции основаны на сочетаниях пептидных фрагментов, полученных из основного аллергена пыльцы амброзии, Amb a 1. Изобретение также относится к продуктам, векторам и составам, которые можно использовать для предоставления полипептидов данного изобретения в сочетаниях. Изобретение также относится к in vitro способам, которые позволяют определить, могут ли Т-клетки распознавать полипептид по данному изобретению, и имеет ли субъект состояние или подвержен ли риску развития состояния, характеризующегося аллергическими симптомами в ответ на аллерген амброзии.
EA201170336A 2008-08-15 2009-08-14 Пептиды амброзии для получения вакцин EA201170336A1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0814986A GB0814986D0 (en) 2008-08-15 2008-08-15 Peptide for il10 production
PCT/GB2008/002779 WO2009022155A2 (en) 2007-08-15 2008-08-15 Peptide with reduced dimer formation
PCT/GB2008/002781 WO2009022157A2 (en) 2007-08-15 2008-08-15 Peptide with improved solubility
GB0815218A GB0815218D0 (en) 2008-08-20 2008-08-20 Ragweed peptides for vaccine
EP09251252.4A EP2153841B2 (en) 2008-08-15 2009-05-01 Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
PCT/GB2009/001986 WO2010018378A2 (en) 2008-08-15 2009-08-14 Ragweed peptides for vaccine

Publications (1)

Publication Number Publication Date
EA201170336A1 true EA201170336A1 (ru) 2011-10-31

Family

ID=41090318

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170336A EA201170336A1 (ru) 2008-08-15 2009-08-14 Пептиды амброзии для получения вакцин

Country Status (18)

Country Link
US (3) US8491910B2 (ru)
EP (3) EP2444100A3 (ru)
JP (1) JP5788319B2 (ru)
KR (1) KR20110044787A (ru)
CN (2) CN102170897B (ru)
AT (1) ATE536880T1 (ru)
AU (1) AU2009281013B2 (ru)
BR (1) BRPI0917648A2 (ru)
CA (1) CA2734379A1 (ru)
DK (1) DK2153841T4 (ru)
EA (1) EA201170336A1 (ru)
ES (1) ES2378870T5 (ru)
HR (1) HRP20120206T4 (ru)
MX (1) MX2011001619A (ru)
PL (1) PL2153841T5 (ru)
PT (1) PT2153841E (ru)
SI (1) SI2153841T2 (ru)
WO (1) WO2010018378A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958645A1 (en) * 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
DK2153841T4 (en) * 2008-08-15 2016-02-15 Circassia Ltd Vaccine comprising Amb a 1 peptides for use in the treatment of ambrosieallergi
US8821887B2 (en) 2008-08-15 2014-09-02 Circassia Limited T-cell antigen peptide from allergen for stimulation of IL-10 production
AU2010342533B2 (en) * 2010-01-14 2017-02-23 Merck Patent Gmbh Variants of the group-5 allergens of the poaceae with reduced allergenicity by mutagenesis of proline residues
FI20115374A0 (fi) * 2011-04-18 2011-04-18 Teknologian Tutkimuskeskus Vtt Oy Uudet hypoallergeenit
JP5897120B2 (ja) * 2011-06-27 2016-03-30 アネルギ エスアー ブタクサ花粉アレルギーの治療のための連続する重複ペプチド
DK2838556T3 (en) * 2012-04-16 2017-04-10 Alk-Abelló As Plant profile polypeptides for use in non-specific allergy immunotherapy
CN110075285A (zh) 2012-10-30 2019-08-02 阿拉沃克斯有限公司 新颖的免疫治疗分子和其用途
US11173206B2 (en) 2013-03-15 2021-11-16 Sementis Limited Immune modulation
CA2925480A1 (en) 2013-09-25 2015-04-02 Aravax Pty Ltd Novel immunotherapeutic composition and uses thereof
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
CN117362453B (zh) * 2023-12-08 2024-02-27 山东硕景生物科技有限公司 一种Derf1重组抗原、其制备方法及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE175209T1 (de) 1989-03-17 1999-01-15 Immulogic Pharma Corp Allergene proteine aus ambrosia und verwendung davon
US5776761A (en) * 1989-03-17 1998-07-07 Immulogic Pharmaceutical Corporation Nucleic acids encoding allergenic proteins from ragweed
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
EP0636180A1 (en) * 1992-04-09 1995-02-01 Immulogic Pharmaceutical Corporation T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA)
JPH07257419A (ja) 1994-03-24 1995-10-09 Kubota Corp 農作業車
US5820862A (en) 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
AU4146796A (en) * 1994-10-27 1996-05-23 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from ambrosia artemisiifolia
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
GB2348808B (en) 1998-01-09 2003-03-19 Circassia Ltd Methods and compositions for desensitisation
US6989146B2 (en) 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
JP4874522B2 (ja) 2001-12-05 2012-02-15 サーカッシア リミテッド 免疫療法および系
AU2003228133A1 (en) 2002-04-22 2003-11-03 Umc Utrecht Holding B.V. Reduction of unwanted immune reactions
GB0210741D0 (en) 2002-05-10 2002-06-19 Medical Res Council Methods of therapy
GB0308988D0 (en) 2003-04-17 2003-05-28 Univ Singapore Molecule
WO2006075253A2 (en) 2005-01-11 2006-07-20 Commissariat A L'energie Atomique Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides.
AU2006220835B2 (en) * 2005-03-04 2012-01-19 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
WO2006132607A1 (en) 2005-06-10 2006-12-14 National University Of Singapore Mutant allergen(s)
US20070092532A1 (en) 2005-10-25 2007-04-26 Board Of Trustees Operating Michigan State University Arthritis vaccines and methods
CN100457180C (zh) * 2005-11-09 2009-02-04 浙江我武生物科技有限公司 用于治疗过敏性疾病的药物组合物及其制备方法
ES2596855T3 (es) 2005-11-29 2017-01-12 Intrexon Actobiotics Nv Inducción de tolerancia mucosa a antígenos
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
US20110038881A1 (en) 2007-05-09 2011-02-17 Circassia Limited Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
PT2083856E (pt) 2007-08-15 2010-12-23 Circassia Ltd Péptidos para a dessensibilização contra alergénios
DK2153841T4 (en) * 2008-08-15 2016-02-15 Circassia Ltd Vaccine comprising Amb a 1 peptides for use in the treatment of ambrosieallergi

Also Published As

Publication number Publication date
AU2009281013A1 (en) 2010-02-18
WO2010018378A3 (en) 2010-07-22
ES2378870T5 (es) 2016-02-03
AU2009281013B2 (en) 2015-01-29
JP2012500193A (ja) 2012-01-05
WO2010018378A2 (en) 2010-02-18
US9347937B2 (en) 2016-05-24
ATE536880T1 (de) 2011-12-15
DK2153841T4 (en) 2016-02-15
KR20110044787A (ko) 2011-04-29
SI2153841T2 (sl) 2016-02-29
DK2153841T3 (da) 2012-03-26
ES2378870T3 (es) 2012-04-18
US20130295123A1 (en) 2013-11-07
JP5788319B2 (ja) 2015-09-30
US20120108524A1 (en) 2012-05-03
CN104710512A (zh) 2015-06-17
PL2153841T5 (pl) 2016-09-30
CN102170897A (zh) 2011-08-31
PL2153841T3 (pl) 2012-05-31
EP2433639A2 (en) 2012-03-28
HRP20120206T1 (en) 2012-03-31
BRPI0917648A2 (pt) 2015-12-01
MX2011001619A (es) 2011-03-25
EP2444100A2 (en) 2012-04-25
CA2734379A1 (en) 2010-02-18
EP2153841A1 (en) 2010-02-17
EP2444100A3 (en) 2012-07-25
PT2153841E (pt) 2012-03-21
WO2010018378A8 (en) 2010-10-28
EP2433639A3 (en) 2012-06-27
EP2153841B1 (en) 2011-12-14
HRP20120206T4 (hr) 2016-02-12
EP2153841B2 (en) 2015-11-11
SI2153841T1 (sl) 2012-04-30
US8491910B2 (en) 2013-07-23
US20170014505A1 (en) 2017-01-19
CN102170897B (zh) 2015-02-04

Similar Documents

Publication Publication Date Title
EA201170336A1 (ru) Пептиды амброзии для получения вакцин
CY1116285T1 (el) Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα
EA200700136A1 (ru) Анти-cd154-антитела
ATE539089T1 (de) Cyclische rezeptor-assoziierte-proteine (rap)- peptide
WO2008098749A3 (en) Peptides derived from the major allergen of ragweed (ambrosia artemisiifolia) and uses thereof
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
MA32770B1 (fr) Anticorps anti-peptides igf-1/e humain modifie
MX2020012569A (es) Moleculas inmunoterapeuticas novedosas y sus usos.
Marzban et al. Identification of four IgE‐reactive proteins in raspberry (Rubus ideaeus L.)
IL177698A0 (en) Fusion proeins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
US20190202875A1 (en) Immunogenic proteins and fragments thereof from allergenic mites
EP3208334A3 (en) Cdc45l peptides and vaccines including the same
Prandi et al. Simulated gastrointestinal digestion of Pru ar 3 apricot allergen: Assessment of allergen resistance and characterization of the peptides by ultra‐performance liquid chromatography/electrospray ionisation mass spectrometry
Postigo et al. Identification of 2 new allergens of Phoenix dactylifera using an immunoproteomics approach
WO2012073045A3 (en) Variants of trappins
WO2012170842A3 (en) Peptide for protection of allergic respiratory disorders
NZ605799A (en) Wdrpuh epitope peptides and vaccines containing the same
WO2015131053A1 (en) Polypeptides derived from phl p and methods and uses thereof for immune response modulation
ATE511643T1 (de) Fragment des neurosekretorischen proteins vgf als biomarker für morbus alzheimer
TH76095A (th) สารประกอบแอลเลอเจนิคโปรตีนจากน้ำนมยางธรรมชาติ
WO2018200814A3 (en) Modified cyclic peptides and therapeutic use thereof
WO2012001179A3 (en) Linear ige peptide epitopes of hazelnut allergen cor a 1 and celery antigen api 1